AcelRx slides after FDA refuses 'EUA' tag to blood thinner device

Talphera

25/09/2023 17:54

** Shares of AcelRx Pharmaceuticals  ACRX.O  fall 10.5% to
62 cents 
    ** Co said on Friday the U.S health regulator had declined
to issue Emergency Use Authorization (EUA) for Niyad, a device
used to deliver co's blood thinner nafamostat
    ** The FDA said review of co's EUA not a priority due to
volume of EUA requests 
    ** Co said it expects to submit a premarket application for
Niyad to the FDA in 2024
    ** Including session moves, shares down 72.3% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))